Intravesical botulinum toxin for lower urinary tract dysfunction.
Botulinum neurotoxin has achieved substantial clinical benefits in neurogenic detrusor overactivity. More contentious has been its extension to management of refractory idiopathic detrusor overactivity, in which risk of impaired voiding function and consequent need for intermittent catheterisation may counteract the quality-of-life benefits of improved storage function. Several issues remain uncertain for this unlicensed treatment, and clear insights into long-term consequences are needed before it can be regarded as an established mainstream treatment.
John Drake
Marcus
M
Bristol Urological Institute Southmead Hospital, Bristol, BS10 5NB UK.